Tag: investors

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investors of the July 28, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

Sydney, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Australian superannuation regulations require self-managed super funds to maintain a documented investment strategy that covers asset allocation, liquidity, diversification, and both income and capital objectives. The Australian Taxation Office mandates that the strategy be reviewed at least annually. For trustees building that strategy around delivering monthly income, the income side of the portfolio will be reviewed closely. The latest ATO data shows the SMSF sector now holds A$1.06 trillion in assets across 663,867 funds, with cash and term deposit allocations falling to 16.3% of holdings, a record low, as trustees look beyond traditional cash products. To learn mroe visit https://termplus.com.au/term-account-smsf/

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Calix, Inc. (“Calix” or the “Company”) (NYSE:CALX) investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development